Global Orphan Drug Market Size, Share, Growth Analysis, By Disease Type(Oncological diseases, metabolic diseases), By Drug Type(Biologics, Non-biologics) - Industry Forecast 2023-2030

To request a free sample copy of this report, please complete the form below.

What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

License Type Top market research company in USA

File Type

Analyst Support

$5,300

BUY NOW

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

SPEAK TO AN ANALYST

FAQ's

Global Orphan Drug Market size was valued at USD 87.44 billion in 2021 and is poised to grow from USD 174.11 billion in 2022 to USD 359.86 billion by 2030, growing at a CAGR of 9.5% in the forecast period (2023-2030).

The Global Orphan Drug Market is relatively fragmented, with a high level of competition. The prominent players operating in the orphan drug market are constantly 'Vertex Pharmaceuticals', 'Alexion Pharmaceuticals', 'BioMarin Pharmaceutical', 'Shire (now part of Takeda)', 'Sanofi Genzyme', 'Celgene (now part of Bristol Myers Squibb)', 'Genentech (a subsidiary of Roche)', 'Pfizer', 'Novartis', 'Johnson & Johnson', 'AbbVie', 'Amgen', 'Ultragenyx Pharmaceutical', 'CSL Behring', 'Merck & Co.', 'Grifols', 'Sobi (Swedish Orphan Biovitrum)', 'Ipsen', 'Jazz Pharmaceuticals', 'AstraZeneca'

The development of orphan medications under research has been significantly influenced by the development of new technologies. Due recent advancements in genomics and the wider application of gene sequencing, made it possible in case of rare disease. furthermore, additional technologies like gene therapy and antisense therapy have made it feasible for us to target certain disorders in ways that were not previously possible. Combined, technological advancements have made it easier to both diagnose and cure uncommon genetic disorders, which has made them more manageable for pharmaceutical companies.

Since companies employ far lower criteria for showing treatment effectiveness, the expansion of the use of auxiliary or surrogate endpoints within clinical trials for orphan pharmaceuticals has significantly reduced the time and cost needed to undertake R&D. This can accelerate the growth of the Orphan Drug Market.

In terms of CAGR, North America is expected to grow quickly in the years to come. This is attributed to the increase in patients in this area who are susceptible to rare diseases. The unhealthy lifestyle and stressful lifestyle are the key factors that cause this disease to spread in this area. In order to reduce the number of patients brought on by this disease, government organisations like NGO are investing a significant amount of money in this region.

Feedback From Our Clients